Feasibility of Long-Term Transfemoral Power Lead for Aortix™ to be Presented at 2015 International Society for Heart and Lung Transplantation Annual Meeting

Is a long-term power lead exiting the femoral artery feasible in powering an intravascular blood pump?

Houston, TX, April 10, 2015 --(PR.com)-- Is a long-term power lead exiting the femoral artery feasible in powering an intravascular blood pump? The team of life scientists behind Houston-based Procyrion, Inc. will answer this question and present their methods of study at the 2015 International Society for Heart and Lung Transplantation (ISHLT) 35th Annual Meeting & Scientific Session in Nice, France on Wednesday, April 15, 2015.

In abstract presentation 469, presenting author Dr. Reynolds M. Delgado III, who is Procyrion’s Founder and Chief Medical Officer, and company co-authors will share their pre-clinical experience with a transfemoral power lead for Aortix™, a long-term circulatory support pump for chronic heart failure patients. During 30 days of observation following percutaneous deployment of the device in large animal studies, subjects showed no bleeding complications, ambulated normally, and were free from infection, swelling, and hemotoma.

“The challenges to this type of mechanical circulatory support implantation include mitigating driveline infection and bleeding risk. While we continue to investigate the safety of this technique, these positive results help us shift focus to other critical areas required to advance this technology,” said Jace Heuring, Ph.D., Chief Operating Officer of Procyrion.

Procyrion’s presentation abstract addressing novel work was reviewed and accepted by the ISHLT Abstract Selection Committee comprised of scientists, infectious disease specialists, tissue engineers, and leading surgeons from around the world.

The International Society for Heart and Lung Transplantation is a multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support, and innovative therapies via research, education, and advocacy.

In June, the Procyrion team will be attending the 2015 Gordon Research Conference (GRC) on Assisted Circulation in Lucca, Italy.

About Procyrion
Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use. The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients. For more information, visit www.procyrion.com or call 713.579.9227.
Procyrion Inc
Anna Drake